Literature DB >> 20056763

Variation in fistula use across dialysis facilities: is it explained by case-mix?

Navdeep Tangri1, Ranjani Moorthi, Hocine Tighiouhart, Klemens B Meyer, Dana C Miskulin.   

Abstract

BACKGROUND AND OBJECTIVES: Arteriovenous fistulas (AVFs) remain the preferred vascular access for hemodialysis patients. Dialysis facilities that fail to meet Centers for Medicare & Medicaid Services goals cite patient case-mix as a reason for low AVF prevalence. This study aimed to determine the magnitude of the variability in AVF usage across dialysis facilities and the extent to which patient case-mix explains it. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The vascular access used in 10,112 patients dialyzed at 173 Dialysis Clinic Inc. facilities from October 1 to December 31, 2004, was evaluated. The access in use was considered to be an AVF if it was used for >70% of hemodialysis treatments. Mixed-effects models with a random intercept for dialysis facilities evaluated the effect of facilities on AVF usage. Sequentially adjusted multivariate models measured the extent to which patient factors (case-mix) explain variation across facilities in AVF rates.
RESULTS: 3787 patients (38%) were dialyzed using AVFs. There was a significant facility effect: 7.6% of variation in AVF use was attributable to facility. This was reduced to 7.1% after case-mix adjustment. There were no identified specific facility-level factors that explained the interfacility variation.
CONCLUSIONS: AVF usage varies across dialysis facilities, and patient case-mix did not reduce this variation. In this study, 92% of the total variation in AVF usage was due to patient factors, but most were not measurable. A combination of patient factors and process indicators should be considered in adjudicating facility performance for this quality indicator.

Entities:  

Mesh:

Year:  2010        PMID: 20056763      PMCID: PMC2827588          DOI: 10.2215/CJN.04430709

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  14 in total

1.  Appropriate assessment of neighborhood effects on individual health: integrating random and fixed effects in multilevel logistic regression.

Authors:  Klaus Larsen; Juan Merlo
Journal:  Am J Epidemiol       Date:  2005-01-01       Impact factor: 4.897

2.  Center effects in anemia management of dialysis patients.

Authors:  Jeffrey C Fink; Van Doren Hsu; Min Zhan; Lori D Walker; C Daniel Mullins; Charlotte Jones-Burton; Patricia Langenberg; Stephen L Seliger
Journal:  J Am Soc Nephrol       Date:  2007-01-17       Impact factor: 10.121

3.  Effect of a vascular access nurse coordinator to reduce central venous catheter use in incident hemodialysis patients: a quality improvement report.

Authors:  Kevan Roy Polkinghorne; Mechelle Seneviratne; Peter G Kerr
Journal:  Am J Kidney Dis       Date:  2008-09-21       Impact factor: 8.860

4.  Vascular access use in Europe and the United States: results from the DOPPS.

Authors:  Ronald L Pisoni; Eric W Young; Dawn M Dykstra; Roger N Greenwood; Erwin Hecking; Brenda Gillespie; Robert A Wolfe; David A Goodkin; Philip J Held
Journal:  Kidney Int       Date:  2002-01       Impact factor: 10.612

5.  Predictors of type of vascular access in hemodialysis patients.

Authors:  R A Hirth; M N Turenne; J D Woods; E W Young; F K Port; M V Pauly; P J Held
Journal:  JAMA       Date:  1996 Oct 23-30       Impact factor: 56.272

6.  Long-term outcomes of a fistula initiative: sustaining "fistula culture".

Authors:  R L McGill; R J Marcus; D A Healy; S Nye; D J Brouwer; B C Smith; S E Sandroni
Journal:  J Vasc Access       Date:  2006 Apr-Jun       Impact factor: 2.283

7.  Impact of surgeon and surgical center characteristics on choice of permanent vascular access.

Authors:  Ann M O'Hare; R Adams Dudley; Denise M Hynes; Charles E McCulloch; Daniel Navarro; Philip Colin; Kevin Stroupe; Joseph Rapp; Kirsten L Johansen
Journal:  Kidney Int       Date:  2003-08       Impact factor: 10.612

8.  AV fistula rates: changing the culture of vascular access.

Authors:  R L McGill; R J Marcus; D A Healy; D J Brouwer; B C Smith; S E Sandroni
Journal:  J Vasc Access       Date:  2005 Jan-Mar       Impact factor: 2.283

9.  Assessing comorbidity using claims data: an overview.

Authors:  Carrie N Klabunde; Joan L Warren; Julie M Legler
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

10.  Hemodialysis adequacy in Network 5: disparity between states and the role of center effects.

Authors:  J C Fink; N Armistead; M Turner; J Gardner; P Light
Journal:  Am J Kidney Dis       Date:  1999-01       Impact factor: 8.860

View more
  11 in total

1.  Vascular access creation before hemodialysis initiation and use: a population-based cohort study.

Authors:  Ahmed A Al-Jaishi; Charmaine E Lok; Amit X Garg; Joyce C Zhang; Louise M Moist
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-07       Impact factor: 8.237

2.  Center-Effect of Incident Hemodialysis Vascular Access Use: Analysis of a Bi-national Registry.

Authors:  Samantha Ng; Elaine M Pascoe; David W Johnson; Carmel M Hawley; Kevan R Polkinghorne; Stephen McDonald; Philip A Clayton; Kannaiyan S Rabindranath; Matthew A Roberts; Ashley B Irish; Andrea K Viecelli
Journal:  Kidney360       Date:  2021-02-09

3.  Organizational status of dialysis facilities and patient outcome: does higher injectable medication use mediate increased mortality?

Authors:  Yi Zhang; Mae Thamer; Onkar Kshirsagar; Dennis J Cotter
Journal:  Health Serv Res       Date:  2012-12-06       Impact factor: 3.402

4.  Variation in the level of eGFR at dialysis initiation across dialysis facilities and geographic regions.

Authors:  Manish M Sood; Braden Manns; Allison Dart; Brett Hiebert; Joanne Kappel; Paul Komenda; Anita Molzahn; David Naimark; Sharon Nessim; Claudio Rigatto; Steven Soroka; Michael Zappitelli; Navdeep Tangri
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-23       Impact factor: 8.237

5.  Geographic and facility-level variation in the use of peritoneal dialysis in Canada: a cohort study.

Authors:  Manish M Sood; Navdeep Tangri; Brett Hiebert; Joanne Kappel; Allison Dart; Adeera Levin; Braden Manns; Anita Molzahn; David Naimark; Sharon J Nessim; Claudio Rigatto; Steven D Soroka; Michael Zappitelli; Paul Komenda
Journal:  CMAJ Open       Date:  2014-03-27

6.  Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease study.

Authors:  L Ebony Boulware; Navdeep Tangri; Patti L Ephraim; Julia J Scialla; Stephen M Sozio; Deidra C Crews; Tariq Shafi; Dana C Miskulin; Jiannong Liu; Wendy St Peter; Bernard G Jaar; Albert W Wu; Neil R Powe; Sankar D Navaneethan; Karen Bandeen-Roche
Journal:  BMC Nephrol       Date:  2012-12-06       Impact factor: 2.388

7.  Geographic and facility variation in initial use of non-tunneled catheters for incident maintenance hemodialysis patients.

Authors:  Edward G Clark; Ayub Akbari; Brett Hiebert; Swapnil Hiremath; Paul Komenda; Charmaine E Lok; Louise M Moist; Michael E Schachter; Navdeep Tangri; Manish M Sood
Journal:  BMC Nephrol       Date:  2016-02-27       Impact factor: 2.388

8.  Prevalence and correlates of central venous catheter use among haemodialysis patients in the Irish health system - a national study.

Authors:  Wael F Hussein; Husham Mohammed; Leonard Browne; Liam Plant; Austin G Stack
Journal:  BMC Nephrol       Date:  2018-04-02       Impact factor: 2.388

9.  Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series.

Authors:  Mae Thamer; Yi Zhang; Dejian Lai; Onkar Kshirsagar; Dennis Cotter
Journal:  BMC Nephrol       Date:  2013-08-09       Impact factor: 2.388

10.  The association between geographic proximity to a dialysis facility and use of dialysis catheters.

Authors:  Lisa M Miller; Lavern M Vercaigne; Louise Moist; Charmaine E Lok; Navdeep Tangri; Paul Komenda; Claudio Rigatto; Julie Mojica; Manish M Sood
Journal:  BMC Nephrol       Date:  2014-02-27       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.